Efficacy and Safety of FS VH S/D 500 S-apr (Tisseel) as an Adjunct to Sutured Dural Repair in Cranial Surgery

Phase 3

Completed

• Conditions: Cerebrospinal Fluid Leak
• Interventions: Device: DuraSeal Dural Sealant; Drug: FS VH S/D 500 s-apr

• Registration Number: NCT02891070
• Lead Sponsor: Baxter Healthcare Corporation

Brief Summary

The objective of this study is to evaluate the safety and efficacy of FS VH S/D 500 s-apr for use as an adjunct to sutured dural repair in cranial surgery.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-09-01
• Study First Submitted QC: 2016-09-01
• Study First Posted: 2016-09-07
• Study Start: 2016-10-11
• Primary Completion: 2018-08-22
• Study Completion: 2018-08-22
• Disposition First Submitted: 2018-11-09
• Disposition First Submitted QC: 2018-11-09
• Disposition First Posted: 2018-11-14
• Status Verified: 2019-08
• Results First Submitted: 2019-08-21
• Results First Submitted QC: 2019-08-21
• Last Update Submitted: 2019-08-21
• Results First Posted: 2019-09-10
• Last Update Posted: 2019-09-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 224

Inclusion Criteria

1. Patients undergoing craniotomy/craniectomy for pathological processes in the PF or ST region
2. Patients must be willing and able to participate in the study and provide written IC before any protocol specific assessment is performed
3. Patients must be willing to receive peri-operative antibiotic prophylaxis
4. Female patients of childbearing potential must present with a negative serum pregnancy test, and must agree to employ adequate birth control measures [restricted to abstinence, barrier contraceptives, intrauterine contraceptive devices or licensed hormonal products] for the duration of their participation in the study
5. Patients are willing and able to comply with the requirements of the protocol

Exclusion Criteria

1. Patients with a dural lesion from a recent surgery that still has the potential for CSF leakage
2. Patients who had undergone chemotherapy treatment, excluding hormonal therapy, within 3 weeks prior to the planned procedure, or with chemotherapy scheduled within 7 days following surgery
3. Patients with radiation therapy to the surgical site or standard fractionated radiation therapy scheduled within 7 days following surgery
4. Patients with a previous craniotomy/craniectomy within 6 months prior to the study surgery
5. Use of corticosteroids on a chronic basis (defined as daily use of corticosteroids for ≥8 weeks) for purposes other than decreasing the symptoms of systemic chemotherapy (unless if those steroids were discontinued 4 weeks prior to the planned surgery)
6. Patients with a known hypersensitivity to the components of the IP or control (human fibrinogen, synthetic aprotinin, human albumin, human FXIII, tri sodium citrate, histidine, niacinamide, polysorbate 80, human thrombin, polyethylene glycol [PEG], trilysine amine)
7. Patients with a known hypersensitivity to US Federal Drug & Cosmetic Blue #1 dye
8. Evidence of an infection indicated by any one of the following: clinical examination supporting the diagnosis of infection, fever (temperature >100.7°F or 38.2°C), positive urine culture, positive blood culture, positive chest X ray consistent with pulmonary infection, or infection along the planned surgical path. A white blood cell (WBC) count of <20000 cells/µL is permitted if the patient is being treated with steroids in the absence of all other infection parameters
9. Female patients of childbearing potential with a positive pregnancy test or intent to become pregnant during the clinical study period
10. Female patients who are nursing
11. Patients with exposure to another investigational drug or device clinical trial within 30 days prior to enrolment or anticipated in the 60-day Follow-up period
12. Patients with severely altered renal function as confirmed by local laboratory reference ranges for serum creatinine and/or hepatic function (alanine aminotransferase [ALT], aspartate aminotransferase >3 × upper limit of normal [ULN])
13. Patients who currently have or have had a compromised immune system (such as Acquired Immune Deficiency Syndrome [AIDS]) or autoimmune disease, or were on chronic immunosuppressant agents
14. Patients with uncontrolled diabetes as evidenced by the institution's standard of care (glycated haemoglobin [HbA1c] >7%, blood glucose, etc.)
15. Patients with traumatic injuries to the head
16. Patients with dural injury during craniotomy/craniectomy that cannot be eliminated by widening the craniotomy/craniectomy to recreate the native dural cuff
17. Patients requiring surgical approaches that would not allow sutured dural closure such as trans-sphenoidal or translabyrinthine/-petrosal/-mastoid. Superficial penetration of mastoid air cells is allowed
18. Patients with hydrocephalus, except occlusive hydrocephalus caused by PF pathology or incompletely open cerebrospinal fluid pathways, to be treated during surgical procedure
19. Existing CSF (ventricular, etc.) drains, Cushing/Dandy cannulation, or Burr holes which damage the dura
20. Patients with confined bony structures where nerves are present and neural compression may result due to swelling

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
DuraSeal Dural Sealant	DuraSeal Dural Sealant	DuraSeal Dural Sealant, single use treatment, intraoperative
FS VH S/D 500 s-apr	FS VH S/D 500 s-apr	FS VH S/D 500 s-apr (Tisseel), single use treatment, intraoperative

Primary Outcome Measures

Name	Time	Method
Number of Participants With No CSF Leak During and After Surgery	Day 0 (Intra-operative) to Day 30 (+/-3 days) post-operative	Participants who have no intra-operative CSF leak from dural repair after up to two applications during Valsalva maneuver (25 cm H2O for up to 5 - 10 seconds), or post-operative CSF leak within 30 (+3) days post-operatively. The Valsalva maneuver was performed by the anaesthesiologist to increase the intra-thoracic pressure (e.g., by increasing the positive end-expiratory pressure or by giving a large tidal volume and holding the inflating pressure) to approximately 25 cm H2O, constantly for up to 5 - 10 seconds to transiently elevate the intracranial pressure and test for any CSF leaks. The suture line was to be watertight after up to two product/control applications and Valsalva maneuvers.

Secondary Outcome Measures

Name	Time	Method
Number of Participants With no Intra-operative CSF Leaks Following Final Valsalva Maneuver	Day 0 (Intra-operative)	Assessment of whether the suture line was not watertight causing CSF leaks after up to two product/control applications and Valsalva maneuvers.
Number of Participants With CSF Leaks Within 30 (+3) Days Post-operatively	Day 0 (Intra-operative) to Day 30 (+/-3 days) post-operative	Cerebrospinal fluid leak was defined as any overt flow, seepage, weeping, or sweating of CSF through the dura suture line, regardless of volume. All post-operative CSF leaks were primarily diagnosed based on a detailed history and physical examination, including neurological examination. Although not standard of care post-operatively, imaging tests such as computed tomography/magnetic resonance imaging (MRI) were considered if there was a high clinical suspicion of a CSF leak.
Time From Dural Closure (Application of IP) Until End of Surgery	Day 0 (Intra-operatively)	Suture closure techniques include continuous simple, continuous locked, interrupted.
Duration in Surgery (Minutes)	Day 0 (intra-operatively)	Patients undergoing elective cranial surgery for the treatment of a pathological condition (e.g., benign/malignant tumours, vascular malformations, or Chiari type 1 malformations) specifically located in the posterior fossa (PF) or supratentorial (ST) regions.
Length of Stay in Hospital (Days).	Day 0 to Day 60 (Study Completion)	Days in hospital calculation is Day 0 - Discharge.

Trial Locations

Locations (25)

University Hospitals Case Medical Center; 🇺🇸 Cleveland, Ohio, United States

University Hospital 12 de Octubre; 🇪🇸 Madrid, Spain

Hospital Clinic I Provincial de Barcelona; 🇪🇸 Barcelona, Spain

University Hospital Ostrava; 🇨🇿 Ostrava, Czechia

University Hospital Rostock; 🇩🇪 Rostock, Germany

University Hospital Foundation Jimenez Diaz; 🇪🇸 Madrid, Spain

University Hospital Leipzig; 🇩🇪 Leipzig, Germany

University Hospital Hradec Kralove; 🇨🇿 Hradec Kralove, Czechia

St. Anne's University Hospital Brno; 🇨🇿 Brno, Czechia

University Hospital Germans Trias I Pujol; 🇪🇸 Badalona, Spain

Hospital Na Homolce; 🇨🇿 Praha 5, Czechia

University General Hospital of Valencia; 🇪🇸 Valencia, Spain

University Hospital Son Espases; 🇪🇸 Palma de Mallorca, Spain

Southern Illinois University School of Medicine; 🇺🇸 Springfield, Illinois, United States

Henry Ford Hospital; 🇺🇸 Detroit, Michigan, United States

University of Minnesota; 🇺🇸 Minneapolis, Minnesota, United States

The Ohio State University; 🇺🇸 Columbus, Ohio, United States

University of Pittsburgh Medical Center; 🇺🇸 Pittsburgh, Pennsylvania, United States

Temple University School of Medicine; 🇺🇸 Philadelphia, Pennsylvania, United States

Houston Methodist Neurological Institute; 🇺🇸 Houston, Texas, United States

University of Virginia School of Medicine; 🇺🇸 Charlottesville, Virginia, United States

University Hospital Brno; 🇨🇿 Brno, Czechia

University Hospital Motol; 🇨🇿 Praha 5 - Motol, Czechia

Hospital Bogenhausen Municipal Hospital; 🇩🇪 Munich, Germany

Baystate Medical Center; 🇺🇸 Springfield, Massachusetts, United States